Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06080061 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase changed: Phase 1 → not applicable
    • Eligibility criteria expanded, about 7 words
  2. Study sites: 1 to 2
    • Eligibility criteria revised
    v9
  3. Site contact updatedv8
  4. Site contact updatedv7
  5. Site contact updatedv6
Show 4 earlier versionsHide 4 earlier versions
  1. 2 versions Re-verified since Feb 6, 2024, no change to tracked fieldsv4-v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 31, 2023 to Oct 25, 2023
    • Site details revised
    v3
  3. Study arms: 3 to 1v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stanford University
634 trials monitored
See 47 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Trial Details
NCT Number NCT06080061
Lead Sponsor Stanford University
Collaborators: LUNGevity Foundation
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov